Pharmacyte Biotech Inc (PMCB)

$1.98

+0.02

(+1.02%)▲

Market is closed - opens 7 PM, 04 Jun 2024

Insights on Pharmacyte Biotech Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 72.6% return, outperforming this stock by 109.9%

Performance

  • $1.92
    $2.00
    $1.98
    downward going graph

    3.03%

    Downside

    Day's Volatility :4.0%

    Upside

    1.0%

    downward going graph
  • $1.76
    $3.23
    $1.98
    downward going graph

    11.11%

    Downside

    52 Weeks Volatility :45.51%

    Upside

    38.7%

    downward going graph

Returns

PeriodPharmacyte Biotech IncIndex (Russel 2000)
3 Months
-3.41%
0.0%
6 Months
-12.39%
0.0%
1 Year
-37.54%
0.0%
3 Years
-34.65%
-22.6%

Highlights

Market Capitalization
16.4M
Book Value
$3.68
Earnings Per Share (EPS)
-1.48
PEG Ratio
0.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-5.24%
Return On Equity TTM
-1.74%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
Diluted Eps TTM
-1.48
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Sell
    0
    0%Buy
    50%Hold
    50%Sell
Based on 6 Wall street analysts offering stock ratings for Pharmacyte Biotech Inc(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
3
3
3
Sell
3
3
3

Technicals Summary

Sell

Neutral

Buy

Pharmacyte Biotech Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Pharmacyte Biotech Inc
Pharmacyte Biotech Inc
-7.91%
-12.39%
-37.54%
-34.65%
-34.65%
Moderna, Inc.
Moderna, Inc.
21.03%
85.08%
14.68%
-28.27%
659.22%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.22%
20.18%
31.88%
93.3%
227.58%
Novo Nordisk A/s
Novo Nordisk A/s
8.85%
34.38%
71.83%
235.07%
463.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
16.81%
34.1%
40.6%
123.97%
174.53%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Pharmacyte Biotech Inc
Pharmacyte Biotech Inc
NA
NA
0.0
0.0
-0.02
-0.05
NA
3.68
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.14
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.89
28.89
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.97
46.97
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.59
29.59
0.53
17.08
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Pharmacyte Biotech Inc
Pharmacyte Biotech Inc
Sell
$16.4M
-34.65%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$54.6B
659.22%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.0B
227.58%
28.89
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$602.6B
463.44%
46.97
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$117.5B
174.53%
29.59
39.46%

Institutional Holdings

  • K2 PRINCIPAL FUND LP

    3.87%

  • Geode Capital Management, LLC

    2.37%

  • Vanguard Group Inc

    2.07%

  • EQUITEC PROPRIETARY MARKETS, LLC

    0.98%

  • Sabby Management LLC

    0.97%

  • Susquehanna International Group, LLP

    0.49%

Company Information

pharmacyte biotech, inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the united states. its cellular therapies are developed based on cell-in-a-box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. the company is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the activation of cancer-killing drugs to the source of the cancer. it is also developing a therapy for type 1 diabetes and insulin-dependent type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant. pharmacyte biotech, inc. has a research agreement with the university of technology, sydney to create a version of melligen cells to treat diabetes; and a research agreeme

Organization
Pharmacyte Biotech Inc
Employees
2
CEO
Mr. Joshua N. Silverman
Industry
Consumer Sundries

Discover More

FAQs